Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EPS (Weighted Average and Diluted) (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with $0.18 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 263.64% year-over-year to $0.18, compared with a TTM value of $0.75 through Dec 2025, up 225.0%, and an annual FY2025 reading of $0.75, up 225.0% over the prior year.
  • EPS (Weighted Average and Diluted) was $0.18 for Q4 2025 at Kiniksa Pharmaceuticals International, down from $0.23 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $3.18 in Q3 2022 and bottomed at -$0.72 in Q1 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.03, with a median of -$0.14 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) skyrocketed 822.73% in 2022, then tumbled 130.56% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.53 in 2021, then soared by 113.21% to $0.07 in 2022, then soared by 414.29% to $0.36 in 2023, then tumbled by 130.56% to -$0.11 in 2024, then surged by 263.64% to $0.18 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for KNSA at $0.18 in Q4 2025, $0.23 in Q3 2025, and $0.23 in Q2 2025.